GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Life Sciences Ltd (NSE:SUVEN) » Definitions » Equity-to-Asset

Suven Life Sciences (NSE:SUVEN) Equity-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Suven Life Sciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Suven Life Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ₹0.00 Mil. Suven Life Sciences's Total Assets for the quarter that ended in Dec. 2024 was ₹0.00 Mil.

The historical rank and industry rank for Suven Life Sciences's Equity-to-Asset or its related term are showing as below:

NSE:SUVEN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47   Med: 0.82   Max: 0.97
Current: 0.91

During the past 13 years, the highest Equity to Asset Ratio of Suven Life Sciences was 0.97. The lowest was 0.47. And the median was 0.82.

NSE:SUVEN's Equity-to-Asset is ranked better than
95.32% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs NSE:SUVEN: 0.91

Suven Life Sciences Equity-to-Asset Historical Data

The historical data trend for Suven Life Sciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Life Sciences Equity-to-Asset Chart

Suven Life Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.84 0.89 0.97 0.95

Suven Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.95 - 0.91 -

Competitive Comparison of Suven Life Sciences's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Life Sciences's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Suven Life Sciences's Equity-to-Asset falls into.


;
;

Suven Life Sciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Suven Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Equity to Asset (A: Mar. 2024 )=Total Stockholders Equity/Total Assets
=2700.406/2849.027
=0.95

Suven Life Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=0/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suven Life Sciences  (NSE:SUVEN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Suven Life Sciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Suven Life Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Life Sciences Business Description

Traded in Other Exchanges
Address
Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.

Suven Life Sciences Headlines

No Headlines